Jun 3, 2019
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
(1:00) - What Can Investors Learn From the ASCO Annual Meeting?
(5:45) - What Is Immunotherapy and What Are The Benefits?
(12:15) - What Companies Are Leading The Way?
(17:50) - AstraZeneca's Early Stage Cancer Treatments
(21:00) - Recent Merger and Acquisitions For Biopharmaceutical Industry
(23:25) - Loncar Cancer Immunotherapy ETF: CNCR